摩根士丹利发布研报称，微创医疗面临持续的国内监管挑战，但在手术机械人(Medbot)、心血管和血管 介入业务的出口动能强劲，预期2026年有望实现收支平衡；又因心律管理(CRM)义务已解决，主要股东 Otsuka已完成撤出，因此将该股目标价由原先8.6港元上调至16港元，相当于预测2027年市盈率约20 倍。维持"与大市同步"评级。 香港联交所最新资料显示，9月24日，微创医疗(00853)股东将股票由花旗银行转入上银国际证券，转仓 市值18.57亿港元，占比7.40%。 ...

摩根士丹利发布研报称，微创医疗面临持续的国内监管挑战，但在手术机械人(Medbot)、心血管和血管 介入业务的出口动能强劲，预期2026年有望实现收支平衡；又因心律管理(CRM)义务已解决，主要股东 Otsuka已完成撤出，因此将该股目标价由原先8.6港元上调至16港元，相当于预测2027年市盈率约20 倍。维持"与大市同步"评级。 智通财经APP获悉，香港联交所最新资料显示，9月24日，微创医疗(00853)股东将股票由花旗银行转入 上银国际证券，转仓市值18.57亿港元，占比7.40%。 ...

Core Viewpoint - Morgan Stanley reports that MicroPort Medical (00853) faces ongoing domestic regulatory challenges but has strong export momentum in surgical robots (Medbot), cardiovascular, and vascular intervention businesses, with a projected break-even in 2026. The target price for the stock has been raised from HKD 8.6 to HKD 16, reflecting a forecasted price-to-earnings ratio of approximately 20 times for 2027. The rating remains "in line with the market" [1] Group 1 - MicroPort Medical's sales forecasts for 2025 to 2027 have been reduced by approximately 2%, indicating an 11% compound annual growth rate from 2024 to 2027 [1] - The expectation for net profit to break even in 2026 remains unchanged, with net profit forecasts for 2026 and 2027 being raised by 151% and 15% respectively from a low base [1] - The discount on the holding company has been narrowed from 40% to 30%, reflecting reduced liquidity concerns, and gross margin forecasts have been adjusted upwards based on guidance [1] Group 2 - Continuous cost-saving measures have led to a corresponding reduction in operating expense forecasts [1] - The company is now projected to achieve operational break-even in 2025 from a low base, with net losses expected to narrow by 93% to approximately USD 55 million in 2025 [1]